D.E. Shaw & Co
JANX icon

D.E. Shaw & Co’s Janux Therapeutics JANX Stock Holding History

D.E. Shaw & Co’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Buy
98,395
+65,688
+201% +$901K ﹤0.01% 3197
2025
Q4 		$451K Buy
+32,707
New +$769K ﹤0.01% 3975
2024
Q4 		– Sell
-83,989
Closed -$3.82M – 4624
2024
Q3 		$3.82M Sell
83,989
-13,834
-14% -$602K ﹤0.01% 2171
2024
Q2 		$4.1M Buy
97,823
+43,185
+79% +$2.03M ﹤0.01% 2015
2024
Q1 		$2.06M Buy
+54,638
New +$1.19M ﹤0.01% 2611
2022
Q2 		– Sell
-11,480
Closed -$165K – 5541
2022
Q1 		$165K Sell
11,480
-16,291
-59% -$267K ﹤0.01% 4915
2021
Q4 		$548K Sell
27,771
-18,385
-40% -$385K ﹤0.01% 4352
2021
Q3 		$998K Buy
+46,156
New +$1.33M ﹤0.01% 3599

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's JANX Position: Q1 2026 in Review

D.E. Shaw & Co increased its Janux Therapeutics (JANX) stake by 201% in Q1 2026, buying an estimated $901K and bringing the position to 98,395 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

D.E. Shaw & Co first reported a position in JANX in Q3 2021 and has held it in 8 quarters since. The position peaked at $4.1M in Q2 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • D.E. Shaw & Co held 98,395 shares of Janux Therapeutics worth $1.37M as of Q1 2026.
  • D.E. Shaw & Co bought 65,688 Janux Therapeutics shares in Q1 2026, an estimated $901K.
  • Janux Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3197 holding.
  • D.E. Shaw & Co first reported a position in Janux Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • D.E. Shaw & Co's Janux Therapeutics position peaked at $4.1M in Q2 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.